Investigation Report on China's Iodixanol Market 2021-2025

Investigation Report on China’s Iodixanol Market 2021-2025

$2600 – $3900

According to CRI’s market research, the sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. Th sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY.

SKU: 2104472 Category: Tags: , ,

Description

Iodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma. It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on. Iodixanol was developed by Nycomed, a Norwegian company, naming VISIPAQUE (Nycomed was acquired by GE after the merge with Amersham, and become GE Healthcare). In 2001, Iodixanol entered the Chinese market. Currently, besides GE Healthcare, the other main manufacturers in China are Jiangsu Hengrui Medicine, Yangtze River Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Beilu Pharmaceutical.

According to CRI’s market research, the sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. Th sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY. The growth rate slowed down last year is because the COVID-19 epidemic causes a reduction in the number of operations in hospitals, which influences the sales of Iodixanol. The CAGR of sales value of Iodixanol in China is 27% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved, the sales of Iodixanol will have a recovery growth from 2021 to 2025. In addition, the sales of Iodixanol will also increase due to the market expansion. According to the research, the sales of contrast agents are directly related to the holding volume of CT and MRI. The holding volume in China is much less than that in developed countries. For example, the holding volume of CT for a million people in China is 1/2 of that in the U.S., and 1/5 of that in Japan. Therefore, the number of equipment still has the potential to increase, which will lead the contrast agent market to expand. Iodixanol, as one of the most popular contrast agents, will continue to grow in the short term.

Topics Covered:
-The impact of COVID-19 on China’s Iodixanol market
– Sales value and volume of China’s Iodixanol 2016-2020
– Competitive landscape of China’s Iodixanol market
– Prices of Iodixanol in China
– Prices of Iodixanol in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Iodixanol market
– Prospect of China’s Iodixanol market from 2021 to 2025

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2016
Base Market Size

573
Currency/Unit

CNY million
Forecast Year

2025
Market Size Forecast

3705
CAGR

23.0%

Table of Contents

Table of Contents 1 Relevant Concepts of Iodixanol 1.1 Indications for Iodixanol 1.2 Development of Iodixanol in China 1.3 Governmental Approval of Iodixanol in China 1.4 The Impact of COVID-19 on Iodixanol sales in China 2 Sales of Iodixanol in China, 2016-2020 2.1 Sales Value of Iodixanol 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Iodixanol 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Iodixanol by Dosage Form in China, 2016-2020 2.3.1 Injection 2.3.2 Analysis of Other Dosage Forms 3 Analysis of Major Iodixanol Manufacturers in China, 2016-2020 3.1 Analysis of Market Share of Major Iodixanol Manufacturers 3.1.1 Investigation on Market Share by Sales Value 3.1.2 Investigation on Market Share by Sales volume 3.2 Jiangsu Hengrui Medicine Co., Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Huiyu (Jiangsu Hengrui's Iodixanol) in China 3.3 GE Healthcare AS 3.3.1 Enterprise Profile 3.3.2 Sales of VISIPAQUE (GE Healthcare's Iodixanol) in China 3.4 Yangtze River Pharmaceutical Group 3.4.1 Enterprise Profile 3.4.2 Sales of Xiansu (Yangtze River's Iodixanol) in China 3.5 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Qingliming (Nanjing CTTQ's Iodixanol) in China 3.6 Beijing Beilu Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Dianchunning (Beijing Beilu's Iodixanol) in China 4 Prices of Iodixanol for Different Manufacturers in China, 2020-2021 4.1 Jiangsu Hengrui Medicine Co., Ltd. 4.2 GE Healthcare AS (VISIPAQUE) 4.3 Yangtze River Pharmaceutical Group (Xiansu) 4.4 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (Qingliming) 4.5 Beijing Beilu Pharmaceutical Co., Ltd. (Dianchunning) 5 Prospect of Chinese Iodixanol drug Market, 2021-2025 5.1 Influential Factors of Chinese Iodixanol Market Development 5.1.1 The Impact of COVID-19 on Chinese Iodixanol Market 5.1.2 Market Drivers and Opportunities 5.1.3 Market Threats and Challenges 5.2 Forecast on Market Size 5.3 Forecast on Market Trend List of Charts Chart Patent Information About Iodixanol Injection Registration in China Chart Sales Value of Iodixanol Injection over the World Chart Sales Value of Iodixanol Injection in China, 2016-2020 Chart Sales Value of Iodixanol Injection in China by Regions, 2016-2020 Chart Sales Volume of Iodixanol Injection in China, 2016-2020 Chart Sales Volume of Iodixanol Injection in China by Regions, 2016-2020 Chart Market Share by Sales Value of Top Iodixanol Manufacturers in China, 2016-2020 Chart Sales Value and Volume of Jiangsu Hengrui's Iodixanol in China, 2016-2020 Chart Sales Value and Volume of VISIPAQUE in China, 2016-2020 Chart Sales Value and Volume of Xiansu in China, 2016-2020 Chart Sales Value and Volume of Qingliming, 2016-2020 Chart Sales Value and Volume of Dianchunning, 2016-2020 Chart Referential Prices of Jiangsu Hengrui's Iodixanol in China, 2020-2021 Chart Referential Prices of VISIPAQUE in China, 2020-2021 Chart Referential Prices of Xiansu in China, 2020-2021 Chart Referential Prices of Qingliming in China, 2020-2021 Chart Referential Prices Dianchunning in China, 2020-2021 Chart Forecast on Sales Value of Iodixanol in China, 2021-2025 Chart Forecast on Sales Volume of Iodixanol in China, 2021-2025

Related products